Get the Stockscreener App
438.75
1.08%
4.69
Pre-market:
438.35
-0.40
-0.09%
United Therapeutics Corp stock is traded at $438.75, with a volume of 882.85K.
It is up +1.08% in the last 24 hours and up +40.52% over the past month.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
See More
Previous Close:
$434.06
Open:
$428.71
24h Volume:
882.85K
Relative Volume:
1.31
Market Cap:
$19.79B
Revenue:
$2.99B
Net Income/Loss:
$1.21B
P/E Ratio:
17.51
EPS:
25.06
Net Cash Flow:
$1.13B
1W Performance:
+8.69%
1M Performance:
+40.52%
6M Performance:
+37.17%
1Y Performance:
+22.60%
1-Day Range:
$425.66
$442.01
1-Week Range:
$402.50
$442.01
52-Week Range:
$266.98
$442.01
United Therapeutics Corp Stock (UTHR) Company Profile
Name
United Therapeutics Corp
Sector
Phone
(301) 608-9292
Address
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
438.75 | 19.63B | 2.99B | 1.21B | 1.13B | 25.06 |
|
ZTS
Zoetis Inc
|
141.67 | 63.20B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.96 | 47.56B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
8.87 | 39.84B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.27 | 22.31B | 16.70B | -157.13M | 1.19B | -0.155 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-21-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-11-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-12-24 | Upgrade | Goldman | Sell → Neutral |
| Feb-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Dec-06-22 | Initiated | UBS | Buy |
| Dec-05-22 | Initiated | Goldman | Sell |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-20-22 | Reiterated | BofA Securities | Underperform |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Feb-11-22 | Initiated | BTIG Research | Neutral |
| Jul-14-21 | Upgrade | Argus | Hold → Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-01-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jun-25-20 | Reiterated | H.C. Wainwright | Neutral |
| Mar-10-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-27-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-31-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-03-19 | Initiated | BofA/Merrill | Underperform |
| Aug-01-19 | Upgrade | Jefferies | Underperform → Hold |
| Aug-01-19 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-01-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| May-17-19 | Upgrade | UBS | Sell → Neutral |
| May-09-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-12-18 | Upgrade | Standpoint Research | Hold → Buy |
| Aug-08-18 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-03-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-22-18 | Reiterated | Barclays | Underweight |
| Jan-18-18 | Resumed | Credit Suisse | Underperform |
| Dec-27-17 | Reiterated | Wedbush | Outperform |
| Apr-27-17 | Reiterated | Wedbush | Outperform |
| Mar-30-17 | Initiated | UBS | Sell |
| Mar-16-17 | Initiated | Credit Suisse | Underperform |
View All
United Therapeutics Corp Stock (UTHR) Latest News
Are Robust Financials Driving The Recent Rally In United Therapeutics Corporation's (NASDAQ:UTHR) Stock? - 富途牛牛
Wedge Capital Management L L P NC Sells 11,432 Shares of United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics stock reaches all-time high at $436.99 By Investing.com - Investing.com Australia
United Therapeutics stock reaches all-time high at $436.99 - Investing.com
United Therapeutics (NASDAQ:UTHR) Hits New 1-Year HighWhat's Next? - MarketBeat
United Therapeutics’ Surge: Is Now the Time? - StocksToTrade
Pallas Capital Advisors LLC Purchases 693 Shares of United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Corp. Forms Golden Cross, Signals Bullish Breakout Ahead - Markets Mojo
United Therapeutics (NASDAQ:UTHR) CEO Sells $1,669,200.00 in Stock - MarketBeat
United Therapeutics (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 4,000 Shares - MarketBeat
United Therapeutics (NASDAQ:UTHR) Director Sells $747,774.00 in Stock - MarketBeat
United Therapeutics Corporation $UTHR Shares Sold by Livforsakringsbolaget Skandia Omsesidigt - MarketBeat
United Therapeutics (NASDAQ:UTHR) EVP Sells $4,467,870.00 in Stock - MarketBeat
Signal Advisors Wealth LLC Purchases Shares of 5,339 United Therapeutics Corporation $UTHR - MarketBeat
Balefire LLC Acquires Shares of 1,307 United Therapeutics Corporation $UTHR - MarketBeat
Martine A. Rothblatt Sells 4,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
Voya Investment Management LLC Boosts Holdings in United Therapeutics Corporation $UTHR - MarketBeat
Olian Judy D., director at United Therapeutics, sells $747k in stock By Investing.com - Investing.com South Africa
Performance Recap: Should I hold or sell United Therapeutics Corporation nowJuly 2025 Chart Watch & Real-Time Stock Price Movement Reports - khodrobank.com
Swing Trade: Is United Therapeutics Corporation stock influenced by commodity prices2025 Winners & Losers & Safe Capital Growth Tips - خودرو بانک
Olian Judy D., director at United Therapeutics, sells $747k in stock - Investing.com India
Insider Sell: Judy Olian Sells Shares of United Therapeutics Cor - GuruFocus
United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 4,000 Shares - MarketBeat
United Therapeutics' TETON-2 Trial Shows Success in IPF Treatment | UTHR Stock News - Stock Titan
Published on: 2025-09-19 10:52:45 - خودرو بانک
Integrated Wealth Concepts LLC Sells 7,962 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Aug Weekly: How cyclical is PG&E Corporation Preferred Security’s revenue stream2025 AllTime Highs & AI Powered Market Entry Strategies - khodrobank.com
United Therapeutics president Michael Benkowitz sells shares worth $3.65m - MSN
United Therapeutics president sells shares worth $3.7 million - MSN
Buybacks Report: Is United Therapeutics Corporation affected by consumer sentimentRisk Management & Verified Entry Point Detection - خودرو بانک
United Therapeutics Corporation $UTHR Shares Acquired by Ashton Thomas Private Wealth LLC - MarketBeat
Acadian Asset Management LLC Has $55.22 Million Stock Holdings in United Therapeutics Corporation $UTHR - MarketBeat
Fred Alger Management LLC Takes Position in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics (NASDAQ:UTHR) Director Jan Malcolm Sells 700 Shares - MarketBeat
United Therapeutics (NASDAQ:UTHR) COO Michael Benkowitz Sells 5,000 Shares - MarketBeat
Insider Selling: United Therapeutics (NASDAQ:UTHR) COO Sells 11,375 Shares of Stock - MarketBeat
Growth Value: What is United Therapeutics Corporation’s valuation compared to sectorRisk Management & Stepwise Swing Trade Plans - خودرو بانک
Swedbank AB Sells 4,992 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Cantor Fitzgerald Raises United Therapeutics (NASDAQ:UTHR) Price Target to $525.00 - MarketBeat
Axiom Investors LLC DE Has $500,000 Stock Holdings in United Therapeutics Corporation $UTHR - MarketBeat
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Purchases 25,289 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Jacobs Levy Equity Management Inc. Grows Stake in United Therapeutics Corporation $UTHR - MarketBeat
Inspire Investing LLC Sells 1,237 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Royal Bank of Canada Purchases 32,867 Shares of United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Corporation $UTHR Shares Sold by Integrated Wealth Concepts LLC - Defense World
Advisors Asset Management Inc. Boosts Stake in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Corp Stock (UTHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):